Company* (Country; Symbol) | University/ Nonprofit@ | Type Of Agreement | Product Area |
Details (Date) |
| | ||||
Accentia Inc.* |
Mayo Foundation for Medical Education and Research |
License agreement |
Accentia will develop and commercialize Mayo's method for treating chronic sinusitis |
The royalty-bearing license for the U.S. and Europe covers a low-dose, topical formulation of amphotericin B (4/13) |
Aegis Therapeutics Inc.* |
University of Alabama at Birmingham |
License agreement |
Aegis licensed technology for noninvasive delivery of peptide and non-peptide drugs |
Aegis has exclusive rights to further develop and commercialize the Intravail technology; terms were not disclosed (4/12) |
AngioGenetics |
Tumor Biology Center Freiburg (Germany) |
Collaboration |
To jointly validate known angiogenesis drugs for cancer, heart diseases and eye diseases |
The drugs were identified using TBCF's Spherogenex screening platform; AngioGenetics acquired rights to those results (5/12) |
Ardais Corp.* |
Duke University Medical Center |
Supply agreement |
Ardais will create a biorepository providing human biomaterials and clinical data for Duke's cancer research |
The deal expands on an existing alliance, and could move beyond cancer; terms were not disclosed (4/19) |
Astex Technology |
The Institute of Cancer Research, the Wellcome Trust and Cancer Research Technology |
Collaboration |
To discover drugs against the cancer target BRAF been ongoing among the three |
Astex will contribute expertise in fragment- based discovery to the collaboration, which already had research centers (3/22) |
BioE Inc.* |
University of Southern California |
Collaboration |
To support development of non-embryonic stem cell therapies for neuro- degenerative diseases |
BioE will provide stem cells derived from umbilical cord blood and related support; terms were not disclosed (3/23) |
Bioenvision |
Southern Research Institute |
Extended option agreement |
To manufacture, market and distribute clofarabine to treat pediatric and adult acute leukemias in Japan and Southeast Asia |
The two parties are actively seeking a co- marketing partner to convert the option into a license on terms to be agreed upon by Bioenvision and SRI (5/18) |
BioLineRx Ltd. (Israel) |
Tel Aviv University and Bar-Ilan University (both in Israel) |
License agreement |
BioLineRx licensed compounds targeting schizophrenia and other neurological disorders |
Terms of the exclusive worlwide license were not disclosed; the compound class was not identified (5/5) |
Bionomics Ltd. (Australia; ASX:BNO) |
Southern Cross University (Australia) |
Collaboration |
To discover drugs targeting epilepsy and anxiety |
Bionomics will screen natural products from the university's collection for activity against biological targets (3/29) |
BTG plc* (UK) |
Cancer Research Technology Ltd. (UK) |
Collaboration |
BTG obtained exclusive worldwide rights to a series of quinazoline antitumor agents |
BTG will be responsible for the development and commercialization of the compounds (5/19) |
BTG plc* (UK) |
King's College London (UK) |
Technology acquisition |
BTG acquired drug discovery programs in the areas of diabetes and neurodegeneration |
BGC20-0402 is an inhibitor of CORE-2 GlcNAc- transferase, applicable in diabetic retinopathy; the other program is in preventing iron-induced neurotoxicity (5/4) |
Cangene Corp. (Canada; TSE:CNJ) |
Defence R&D Canada |
Collaborations |
One project, with the University of British Columbia, will be to identify structural information about anthrax |
The second project is to use Cangene's expertise in antibodies to investigate potential treatments for smallpox exposure; terms were not disclosed (4/28) |
Cel-Sci |
Naval Medical Research Center |
Collaborative Research and Development Agreement |
To jointly evaluate CEL- 1000 with new adjuvants against malaria-causing Plasmodium |
Tests will start in mice and could move on to primates; terms were not disclosed (4/28) |
Chemical Diversity Labs Inc.* |
Brigham and Women's Hospital |
Collaboration |
To discover new tools for understanding and treating neuro-degenerative diseases |
CDL will design and supply a small-molecule discovery library for screening by the Laboratory for Drug Discovery in Neuro-degeneration (4/6) |
CombiMatrix Group (unit of Acacia Research Corp.; CMBX) |
Oklahoma State University |
Collaboration |
To characterize influenza A viruses at the genomic level |
University researchers will use CombiMatrix's Bird Flu Custom-Array devices in the work; terms were not disclosed (3/26) |
CombiMatrix Group (unit of Acacia Research Corp.; CMBX) |
Retrovirology Laboratory irsiCaixa (Spain) |
Expanded collaboration |
To conduct initial efficacy screening of siRNA compounds against hepatitis C virus |
The parties will continue their work in the area of HIV; terms were not disclosed (3/23) |
Cognia Corp.* |
Harvard Medical School, Yale Medical School and SUNY Binghamton |
License agreements |
The universities licensed the Cognia Molecular information-management system |
Terms were not disclosed (4/22) |
Crucell NV (the Netherlands; CRXL) |
Aeras GlobalTB Vaccine Foundation |
Collaboration |
Deal focused on improving the Bacillus Calmette-Guérin vaccine using Crucell's PER.C6 and AdVac technologies |
Crucell can earn up to $2.9M by reaching development milestones in the project, which aims to improve the only approved TB vaccine (3/24) |
Debiopharm SA* (Switzerland) |
Shanghai Institute of Materia Medica (China) |
License agreement |
Debiopharm exercised its option to license ZT-1, a cholinesterase inhibitor for treating Alzheimer's disease |
Debiopharm has exclusive worldwide rights to develop and commercialize ZT-1, except in China; SIMM will supply the huperzine A derivative for the product (5/12) |
Echelon Biosciences Inc.* |
University of Texas M. D. Anderson Cancer Center |
Collaboration |
To advance cell- signaling compounds in cancer through preclinical testing |
M.D. Anderson will conduct trials of resulting candidates; Echelon has an option to issue the center a warrant for stock in exchange for commercialization rights (4/19) |
Entercel Ltd.* (formed by Emergent Technologies Inc.) |
University of Texas at Austin |
License agreement |
Entercel licensed a chemical-based platform that adjusts a cell's ability to resist foreign compounds |
Emergent formed Entercel Ltd. to commercialize the technology, which is expected to have applications in agriculture (4/29) |
Emergent Technologies Inc.* |
Texas Tech University Health Sciences Center |
License agreement |
Emergent licensed antibody drug discovery technology |
ETI formed Receptor Logic Ltd. to commercialize the technology, which will be used to design customized treatments for cancer and infectious diseases (3/26) |
Entelos Inc.* |
Massachusetts Institute of Technology |
Collaboration |
To build in silico models for immunology research |
Entelos will provide MIT with a biological modeling platform for work focused on the breakdown of intracellular signaling (3/30) |
Enzo Biochem Inc. (NYSE:ENZ) |
University of Connecticut Health Center |
License and development agreement |
To develop therapeutics for the stimulation and enhancement of bone formation |
Enzo gets an exclusive license to the technology, which relates to modulating signaling pathways in cell development and differentiation (4/21) |
EraGen Biosciences Inc.* |
Emory University |
Collaboration |
To develop a geno-typing system for early detection of HIV variants |
EraGen will provide genotyping systems for HIV, and Emory will provide expertise and testing results (3/22) |
Eurand International SpA* (Italy) |
University of Urbino Biotechnology Centre (Italy) |
Research agreement |
To evaluate a cancer compound derived from indol-3-carbinol, which is present in cruciferous vegetables |
Eurand has an option for exclusive worldwide rights; it would fund development and pay milestones and royalties to the university (4/14) |
Genaissance Pharmaceuticals Inc. (GNSC) |
University of Utah and Yale University |
Amended license agreement |
They simplified terms on the royalty rate on genetic tests and extended Genaissance's rights under the deal |
The license involves patents related to five cardiac ion channel genes originally licensed by DNA Sciences Inc. in March 2003 (4/29) |
Genaissance Pharmaceuticals Inc. (GNSC) |
University of Rochester and the Mayo Foundation for Medical Education and Research |
Access agreements |
Genaissance gets access to clinical expertise, research samples and disease-associated mutations for developing tests for cardiac conditions |
The first product is expected to be a genetic test for cardiac ion channel mutations; terms of the agreements were not disclosed (4/6) |
GenoMed Inc. (Pink sheets:GMED) |
McGill University and Genome Quebec Innovation Centre (Canada) |
Service agreement |
The Genome center will perform large-scale screening projects for GenoMed |
GenoMed's genotyping consists of two stages: screening a number of single nucleotide polymorphisms and validating a smaller number of them (5/19) |
Genomics Collaborative Inc.* |
Whitehead Institute for Biomedical Research |
Collaboration |
Partnership to study the human Y chromosome's role in male infertility |
They will start with a pilot study of DNA samples from 4,000 U.S. males, and expand the work if that proves successful (3/22) |
Geron Corp. (GERN) |
American Type Culture Collection |
License agreement |
ATCC got a license to create and distribute cell lines immortalized with human telomerase reverse transcriptase |
The nonexclusive license, which includes the hTERT gene itself, covers only the market for research use (4/10) |
Gilead Sciences Inc. (GILD) |
Southern ResearchInstitute |
Collaboration |
The institute will do early chemistry and screening work for Gilead |
The deal extends an earlier contract and involves support for Gilead's drug discovery efforts; terms were not disclosed (4/19) |
GTC Biotherapeutics Inc. (GTCB) |
Mayo Clinic |
Collaboration |
Mayo will conduct preclinical tests of GTC's antibody to CD137 for cancer applications |
Work on the agonistic antibody is being funded by a National Institutes of Health grant (5/4) |
Hard to Treat Diseases Inc. (OTC BB:HTDS) |
University of Colorado and the Denver Veteran's Affairs Medical Center |
Material transfer agreement and a sponsored R&D agreement |
They will study the effect of the immunostimulant Tubercin on a variety of diseases |
The deal has a two-year term, and was made with the university's Health Science Centers; terms were not disclosed (5/3) |
Health Discovery Corp. (OTC BB: HDVY) |
University of Miami |
Agreement |
Deal to use Health Discovery's Fractal Genomics Modeling to identify new patterns of biomarkers |
The focus is on AIDS- related dementia; any discoveries from the effort would be jointly owned (3/23) |
Health Discovery Corp. (OTC BB: HDVY) |
Stanford University |
Agreement |
Deal to use Health Discovery's Fractal Genomics Modeling to identify new patterns of biomarkers |
The focus is on lymphatic insufficiency; any products developed using the technology would be jointly owned (3/22) |
HP (NYSE:HPQ) |
The Center for the Advancement of Genomics |
Collaboration |
To advance medical and genomic discoveries |
They will combine their expertise to design new solutions in genome sequencing and other areas (3/31) |
Intercell AG* (Austria) |
Statens Serum Institut (Denmark) |
License agreement |
For development of a prophylactic tuberculosis vaccine |
The vaccine combines TB antigens developed by SSI with Intercell's synthetic immunizer IC 31 as adjuvant; Intercell gets up- front and milestone payments, and would share in any profits (3/17) |
Invitrogen Corp. (IVGN) |
National Human Genome Research Institute and the National Cancer Institute |
Access agreement |
The institutes gained access to Invitrogen's Gateway and Super-Script technologies |
The institutes will use the technology with their Mammalian Gene Collection Program and be able to deliver resulting clones to the academic community (5/4) |
Lorus Therapeutics Inc. (Canada; TSE:LOR) |
University of Toronto |
Collaboration |
The university will help with development and delivery strategies for Lorus compounds |
The newly discovered, low- molecular-weight compounds have shown anticancer and antibacterial properties; the work will be funded in part through a grant (5/12) |
Lynx Therapeutics Inc. (LYNX) |
National Cancer Institute and various institutions |
Contract |
Lynx will apply its Massively Parallel Signature Sequencing technology to characterize genomic changes in cancer |
Lynx will receive payments for the DNA-sequencing services; Lynx also signed new deals with the National Institute of Environmental and Health Sciences and the Howard Hughes Medical Institute, and extended deals with the Ludwig Institute for Cancer Research and the National Institute on Aging (5/13) |
Millennium Pharmaceuticals Inc. (MLNM) |
National Cancer Institute |
Cooperative Research and Development Agreement |
To study the link bet- ween angiotensin-con- verting enzyme 2 and the SARS virus |
The NCI will conduct cell-based studies to identify the structure of the ACE2/SARS complex; Millennium has an option to license resulting discoveries (4/1) |
Myriad Genetics Inc. (MYGN) |
Not disclosed |
License agreement |
Myriad licensed U.S. rights to detect mutations in the Mut Y Homolog gene |
Myriad intends to add the test to its Colaris product line for detecting hereditary colon cancer; terms were not disclosed (4/14) |
NeoRx Corp. (NERX) |
The University of Missouri |
Manufacturing and supply agreement |
The university will supply the radioisotope holmium-166 for Phase III trials of NeoRx's STR |
The university's Columbia Res- earch Reactor Center will supply the product for trials in cancer under undisclosed terms (3/22) |
Norak Biosciences Inc.* |
Development Center for Biotechnology (Taiwan) |
Nonexclusive license agreement |
DCB got certain rights to use Transfluor technology for screening GPCRs |
DCB is a government-funded, nonprofit research organization; terms of the deal were not disclosed (4/6) |
Nuevolution A/S* (Denmark) |
Scripps Research Institute |
License agreement |
Nuevolution got rights to patents related to generating and screening bi-functional molecules |
The molecular evolution technology will be used to generate millions of drug-like molecules; terms were not disclosed (5/13) |
OriGene Technologies Inc.* |
The Translational Genomics Research Institute |
Technology acquisition |
The institute acquired the TrueClone Collection of human cDNA clones |
The clones will be used in high- throughput drug target discovery and development (5/5) |
OriGene Technologies Inc.* |
Riken Protein Research Group (Japan) |
Technology acquisition |
Riken acquired the TrueClone Collection of 20,000 full-length human cDNA clones |
The clones will be used in structural proteomics and related protein functional analysis programs (3/30) |
Panacea Pharmaceuticals Inc.* |
Universty of Texas M.D. Anderson Cancer Center |
Collaboration |
To further explore the biology of human aspartyl beta-hydroxylase regulation and expression in lung carcinomas |
The collaboration also will explore the efficacy of compounds aimed at inhibiting HAAH activity; HAAH rights are owned by Panacea (5/3) |
ParAllele BioScience Inc.* |
National Cancer Institute |
Early access agreement |
The NCI will use the company's MegAllele SNP genotyping platform |
Terms were not disclosed (5/12) |
Peregrine Pharmaceuticals Inc. (PPHM) |
The Foundation Fighting Blindness |
Agreement |
The foundation will conduct preclinical studies of Vascular Targeting Agent technology for eye diseases |
The technology will be tested in angiogenesis-dependent conditions; terms were not disclosed (4/28) |
Prolexys Pharmaceuticals Inc.* |
Arizona State University |
Research collaboration |
To discover peptides and small molecules that modulate vascular tone and can treat conditions associated with vaso- spasm and vasoconstriction |
Prolexys will assist in characterizing and isolating protein interactors involved in a pathway discovered at ASU's Arizona Biodesign Institute; terms of the deal were not disclosed (4/6) |
Protagen AG* (Germany) |
German Resource Center for Genome Research (RZPD) |
License agreement |
Protagen provided RZPD its UNIclone technology for creating non-redundant gene libraries |
Up to 12 more libraries from human, rat and murine tissues will be created under the deal; they also will offer contract manufacturing of recombinant proteins (4/5) |
Samaritan Pharmaceuticals Inc. (OTC BB:SPHC) |
Georgetown University |
License agreement |
Samaritan got licenses to develop and sell drug candidates for treating HIV resistance |
Samaritan got exclusive world- wide rights in exchange for royalties and payments if the drugs are partnered (5/13) |
Seattle Genetics Inc. (SGEN) |
Imperial College Innovations Ltd. |
License agreement |
For exclusive rights to a monoclonal antibody targeting a cell-surface, tumor-associated antigen |
The company plans to evaluate the therapeutic potential of the antibody against a variety of cancers, including hematologic malignancies and solid tumors, such as breast, colon and bladder cancer; Seattle Genetics has development, manufacturing and worldwide commercialization rights, and Imperial College will receive an up-front fee, milestone payments and potential royalties (5/19) |
Senetek plc (SNTK) |
Unnamed research foundation |
Agreement extension |
Senetek's license covers manufacturing and sales of monoclonal antibodies used in disease research |
The license for three cell lines was extended from July 2004 through September 2005; the foundation gets an extension fee and royalties on sales (5/12) |
Targeted Molecular Diagnostics LLC* |
Johns Hopkins University and the Weizmann Institute of Science (Israel) |
Collaboration |
To identify the role of the Epigen ligand in the clinical behavior of prostate cancer |
The goal is to develop markers for prostate cancer; terms were not disclosed (3/22) |
Tm Bioscience Corp. (Canada; TSE:TMC) |
University of Louisville Medical School |
Supply agreement |
Tm is providing its Tag-It P450-2D6 Mutation Detection Kit |
Kits covered under the two-year contract identify mutations com- mon in patients with atypical drug metabolism (4/29) |
Toxin Alert Inc. (Canada; TSE:TOX) |
Mississippi State University |
Development agreement |
To develop large-scale antibody production from plants |
The parties will seek U.S. funding of $2M per year for the work; Toxin Alert would use the anti- bodies for detecting pathogens in food (4/12) |
Viragen Inc. (AMEX:VRA) |
University of Miami |
Agreement extension |
Deal covers a novel form of an immune-enhancing drug (IEP 11) that has shown activity in cancer |
Viragen continues to have an option to acquire exclusive worldwide rights to the small peptide molecule (5/12) |
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
